Article: New Delhi, Oct 19 (PTI) Pharma major Ranbaxy laboratories Ltd has announced the successful completion of the Proof of Concept (POC) Phase II studies of its anti-malarial molecule, RBx 11160.

The molecule, jointly developed by the company and Medicines of Malaria Venture in Geneva, was found to be safe and effective in reducing malaria parasite count, the company informed the Bomaby Stock Exchange today.

"Progress on RBx 1160, which is emerging as a potential anti-malarial New Chemical Entity candidate, will ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!